Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value

The use of antibiotics in Italy: National Report - Year 2020

On 10 March 2022, the 'National Report on the Use of Antibiotics in Italy -2020' was presented on AIFA's YouTube channel ...
Read more "

Appeal by Bayer VS Ministry of Health, MEF and AIFA on the new P&R criteria - Council of State ruling

On 7 January 2022, the Council of State issued its judgment (15 March 2021, no. 3095) on the appeal filed by ...
Read more "

Why this agenda

The year 2021 was the year of starting again, of picking everything up where we left off, while finding that someone or something ...
Read more "

New criteria for access to the 5% fund of Law 326/2003

On 30 November 2021, AIFA defined the new access criteria for Law 326/2003. This law was supplemented by Law ...
Read more "

Summary of the Consolidated Text on Rare Diseases

On 26 May 2021, the Chamber of Deputies, after more than two years of work in the Social Affairs Committee, approved the bill ...
Read more "

Pharma Value Code of Ethics

Being aware of the right value of a drug is a conviction that has inspired Pharma Value's actions, ever since the choice of the ...
Read more "

Our meeting staff in Florence

Today from our LinkedIn page we are not telling you what is happening in the pharma world but what is happening at home ...
Read more "
SPECIAL DRUG EVALUATION COMMISSIONS. AIFA commissions from 2004 to 2021

SPECIAL DRUG EVALUATION COMMISSIONS. AIFA commissions from 2004 to 2021

NOMOS Centro Studi Parlamentari e Pharma Value hanno realizzato uno speciale sulle commissioni per la valutazione dei farmaci, precisamente la Commissione Tecnico ...
Read more "

Thoughts, the Newsletter

Pensierini sarà la Newsletter di Valeria Viola, una mail che non racconterà specificamente le attività di Pharma Value, così come non sarà ...
Read more "
en_GB